HomeAI · summaries
Storia in 3 fonti
Otsuka succeeds with kidney drug; BioNTech downgrades revenue projection
Otsuka's Voyxact met Phase 3 VISIONARY endpoint in IgAN; BioNTech cuts revenue forecast; Lisata sues Kuva Labs; and more
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercepharma.com
In a first, Otsuka’s Voyxact stabilizes IgAN patients’ kidney function decline to normal levels
In a milestone for IgA nephropathy, Otsuka’s Voyxact has shown for the first time in a phase 3 trial that a drug can stabilize patients’ kidney function decline to the normal rate…
- ·
morningstar.com
Otsuka Unveils Unprecedented Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Stabilizes Kidney Function…
